OnKure Therapeutics Statistics
Total Valuation
OKUR has a market cap or net worth of $168.05 million. The enterprise value is -$5.40 million.
| Market Cap | 168.05M |
| Enterprise Value | -5.40M |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OKUR has 40.40 million shares outstanding. The number of shares has increased by 126.66% in one year.
| Current Share Class | 40.40M |
| Shares Outstanding | 40.40M |
| Shares Change (YoY) | +126.66% |
| Shares Change (QoQ) | +264.69% |
| Owned by Insiders (%) | 10.31% |
| Owned by Institutions (%) | 31.02% |
| Float | 17.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 272.10 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.75, with a Debt / Equity ratio of 0.01.
| Current Ratio | 26.75 |
| Quick Ratio | 26.55 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,767.50 |
Financial Efficiency
Return on equity (ROE) is -46.91% and return on invested capital (ROIC) is -30.82%.
| Return on Equity (ROE) | -46.91% |
| Return on Assets (ROA) | -29.26% |
| Return on Invested Capital (ROIC) | -30.82% |
| Return on Capital Employed (ROCE) | -35.98% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +91.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +91.92% |
| 50-Day Moving Average | 4.24 |
| 200-Day Moving Average | 3.58 |
| Relative Strength Index (RSI) | 50.21 |
| Average Volume (20 Days) | 131,088 |
Short Selling Information
The latest short interest is 1.18 million, so 2.93% of the outstanding shares have been sold short.
| Short Interest | 1.18M |
| Short Previous Month | 878,668 |
| Short % of Shares Out | 2.93% |
| Short % of Float | 6.71% |
| Short Ratio (days to cover) | 2.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.14M |
| Pretax Income | -58.71M |
| Net Income | -58.71M |
| EBITDA | -61.74M |
| EBIT | -62.14M |
| Earnings Per Share (EPS) | -$2.59 |
Balance Sheet
The company has $176.39 million in cash and $926,000 in debt, with a net cash position of $175.46 million or $4.34 per share.
| Cash & Cash Equivalents | 176.39M |
| Total Debt | 926,000 |
| Net Cash | 175.46M |
| Net Cash Per Share | $4.34 |
| Equity (Book Value) | 172.11M |
| Book Value Per Share | 4.25 |
| Working Capital | 171.03M |
Cash Flow
In the last 12 months, operating cash flow was -$47.84 million and capital expenditures -$23,000, giving a free cash flow of -$47.86 million.
| Operating Cash Flow | -47.84M |
| Capital Expenditures | -23,000 |
| Depreciation & Amortization | 403,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -47.86M |
| FCF Per Share | -$1.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OKUR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -126.66% |
| Shareholder Yield | -126.66% |
| Earnings Yield | -34.52% |
| FCF Yield | -28.14% |
Analyst Forecast
The average price target for OKUR is $19.50, which is 368.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.50 |
| Price Target Difference | 368.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |